Prostate Cancer Connect
  • Saved

1yr
Impact of Phase III Trials on Hormone Therapy for Prostate Cancer

Recent Phase III trials, such as ARAMIS and ARASENS, have significantly influenced treatment protocols for prostate cancer. These trials provide critical insights into the efficacy of hormone therapies in managing both non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). 

ARAMIS Trial Key finding: Patients with nmCRPC who received early treatment with an androgen receptor inhibitor (AR inhibitor) experienced a significant improvement in progression-free survival compared to those who received delayed treatment.

ARASENS Trial Key finding: Patients with mHSPC who received a combination of hormone therapy and docetaxel demonstrated improved overall survival and progression-free survival compared to those who received hormone therapy alone.

The outcomes from these studies are shifting clinical practices, leading to more tailored and effective treatment regimens. As these trials guide therapeutic decisions, it is crucial to consider how these findings align with current clinical guidelines and patient-specific factors.

How have the findings from these trials influenced your prescribing practices for hormone therapies? What changes have you made or are you considering in your treatment approach based on this evidence?

  • 1yr
    Nubeqa has been proven effective in the key end point of progression free survival advantage in the metastatic, castrate sensitive, and the non-metastatic castrate resistant settings.
  • 1yr
    I have adopted both trials in clinical practice and am pleased with the tolerable side effects of ARI with or without chemotherapy. It has definitely improved outcomes and QOL in Show More

Show More Comments

  • Saved

1yr
Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium - PubMed

Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38248785/

With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In...

The PRAISE-U project review found significant variations in PSA-based prostate cancer screening policies across nine EU countries, highlighting issues of opportunistic screening, overdiagnosis, and the need for standardized guidelines.

  • Saved

1yr
Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review - PubMed

Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38534956/

Neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming...

Neuroendocrine prostate cancer (NEPC) increasingly complicates diagnosis, often presenting with paraneoplastic syndromes. Cushing's Syndrome is most common, highlighting the need for research on targeted treatments to improve survival.

  • Saved

1yr
Screening guidelines for individuals at increased risk for prostate cancer - PubMed

Screening guidelines for individuals at increased risk for prostate cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38896481/

Individuals at increased risk for prostate cancer (PCa) are inconsistently defined in national and international guidelines. The National Comprehensive Cancer Network (NCCN) defines people at increased risk for PCa to...

Guidelines for prostate cancer risk and screening vary. NCCN identifies high-risk groups and recommends PSA and digital rectal exams starting at age 40, emphasizing the need for patient registries.

  • Saved

1yr
Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials

Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials

Source : https://pubmed.ncbi.nlm.nih.gov/38383277/

We found a significantly increased risk of both fractures and falls with a combination of novel androgen signalling inhibitors and traditional forms of hormone therapy.

The addition of androgen receptor signalling inhibitors to standard androgen deprivation therapy significantly increases the risk of fractures and falls in men with prostate cancer, particularly in metastatic disease settings.